NASDAQ:VECT VectivBio (VECT) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free VECT Stock Alerts $16.85 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$16.85▼$16.8550-Day Range$16.85▼$16.8552-Week Range$4.25▼$16.98VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get VectivBio alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About VectivBio Stock (NASDAQ:VECT)VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.Read More VECT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VECT Stock News HeadlinesMay 7, 2024 | americanbankingnews.comVectivBio (NASDAQ:VECT) versus Ginkgo Bioworks (NYSE:DNA) Critical AnalysisApril 5, 2024 | uk.finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthMay 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 18, 2024 | msn.comPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsMarch 1, 2024 | msn.comUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyFebruary 29, 2024 | reuters.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | benzinga.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | ft.comOnly two sleeps left until February 31!May 11, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.February 22, 2024 | finance.yahoo.comShort Bowel Syndrome Market Size and Share is Anticipated to Surge During the Study Period (2020–2034) | DelveInsightFebruary 16, 2024 | finance.yahoo.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call TranscriptDecember 13, 2023 | msn.comIronwood seals the deal on VectivBio mergerDecember 12, 2023 | finance.yahoo.comIronwood Announces the Completion of Squeeze-Out Merger With VectivBioNovember 15, 2023 | tmcnet.comReverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous CytokinesNovember 10, 2023 | msn.comIronwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesNovember 10, 2023 | markets.businessinsider.comAkash Tewari’s Buy Rating on Ironwood Pharma: Linzess Floor Trading and Apraglutide’s Promising FutureNovember 10, 2023 | markets.businessinsider.comHold Rating for Ironwood Pharma Driven by Stable Linzess Revenue and Anticipated Apraglutide Data, Despite T Cell Data DelayNovember 9, 2023 | finance.yahoo.comIronwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year GuidanceOctober 27, 2023 | msn.comIronwood Pharmaceuticals: The Right Play NowOctober 16, 2023 | markets.businessinsider.comIronwood Pharmaceuticals’ Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler’s Buy RatingSeptember 7, 2023 | finance.yahoo.comWhy Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?August 23, 2023 | markets.businessinsider.comEQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor RelationsAugust 23, 2023 | finance.yahoo.comAbivax Appoints Patrick Malloy as Senior Vice President Investor RelationsAugust 9, 2023 | msn.comIronwood's (IRWD) Reports Q2 Loss, Linzess Volume RisesAugust 9, 2023 | uk.finance.yahoo.comQ2 2023 Ironwood Pharmaceuticals Inc Earnings CallJuly 16, 2023 | theglobeandmail.comInstrument Name Vectivbio Holding Ag Instrument Symbol (VECT-Q)June 29, 2023 | finance.yahoo.comIronwood and VectivBio Announce the Completion of the Tender Offer for VectivBio SharesSee More Headlines Receive VECT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VECT CUSIPN/A CIK1836379 Webvectivbio.com Phone41-61-551-3030FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$27.34 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book2.69Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Luca Santarelli M.D. (Age 53)Founder, CEO & Director Ms. Claudia D'Augusta Ph.D. (Age 53)Chief Financial Officer Dr. Christian Meyer M.D. (Age 56)Ph.D., Chief Operating Officer Dr. Alain Bernard Ph.D. (Age 66)Chief Technology Officer Mr. Patrick MalloySr. VP of Investor Relations & Strategic CommunicationsMr. Scott Applebaum (Age 56)Chief Legal Officer & Corp. Sec. Mr. Michael SteiningerSr. VP & Head of HRMr. Kevin Harris M.B.A. (Age 52)Chief Commercial Officer Dr. Sarah Holland Ph.D. (Age 60)Chief Bus. Officer Dr. Omar Khwaja M.D. (Age 53)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsGenocea BiosciencesNASDAQ:GNCAQ180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWView All Competitors VECT Stock Analysis - Frequently Asked Questions Should I buy or sell VectivBio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" VECT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VECT, but not buy additional shares or sell existing shares. View VECT analyst ratings or view top-rated stocks. How have VECT shares performed in 2024? VectivBio's stock was trading at $16.85 on January 1st, 2024. Since then, VECT stock has increased by 0.0% and is now trading at $16.85. View the best growth stocks for 2024 here. When did VectivBio IPO? VectivBio (VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager. How do I buy shares of VectivBio? Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VECT) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceBill Clinton Backing Biden Replacement???The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.